Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-88

Yes, I expect this would undoubtedly be a trading halt pending an update to the market. It should certainly be price-sensitive - good or bad
I was expecting new to drop by now, so starting to wonder a little.
Could PAR have had to reply to a rcent FDA query, and we are now in another response cycle delay?

I'd like to think we would have been told if the FDA had interim questions, but I'm not sure if they are obliged to disclose this?

So, rather than catastrophising, I fall back to my thoughts about the news we know about, and I maintain that there has been no news indicating that this has been derailed other than the threat of time and dollars.

It's quite exciting, really, and regardless of how it goes, I'd rather bin in this than out of it.